Venture Capital
Cancer detection startup Grail today filed to go public as the Silicon Valley biotech aims to raise more funding for its blood test. The company’s backers include Microsoft co-founder Bill Gates and Amazon CEO Jeff Bezos; both invested in a $100 million Series A round four years ago. Total funding is now north of $1.9 billion, including a $390 million Series D round in May. Grail does not have revenue or a commercially-available product. That reflects the traditional life cycle of biotech companies, which commonly invest in research and development for years before bringing products to market.